# Open-label Extension Study of Pramipexole in the Treatment of Children and Adolescents With Tourette Syndrome

> **NCT00681863** · PHASE3 · TERMINATED · sponsor: **Boehringer Ingelheim** · enrollment: 45 (actual)

## Conditions studied

- Tourette Syndrome

## Interventions

- **DRUG:** pramipexole 0.125 mg BID
- **DRUG:** pramipexole 0.0625 mg QD
- **DRUG:** pramipexole 0.125 mg TID
- **DRUG:** pramipexole 0.25 mg BID
- **DRUG:** pramipexole 0.0625 mg BID

## Key facts

- **NCT ID:** NCT00681863
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-05
- **Primary completion:** 2009-10
- **Final completion:** —
- **Target enrollment:** 45 (ACTUAL)
- **Why stopped:** Terminated for slow enrollment.
- **Last updated:** 2014-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00681863

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00681863, "Open-label Extension Study of Pramipexole in the Treatment of Children and Adolescents With Tourette Syndrome". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT00681863. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*